Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator

被引:12
|
作者
Daimee, Usama A. [1 ]
Vermilye, Katherine [1 ]
Moss, Arthur J. [1 ]
Goldenberg, Ilan [1 ]
Klein, Helmut U. [1 ]
McNitt, Scott [1 ]
Zareba, Wojciech [1 ]
Kutyifa, Valentina [1 ]
机构
[1] Univ Rochester, Med Ctr, Div Cardiol, Heart Res Follow Up Program, 265 Crittenden Blvd,Box 653, Rochester, NY 14642 USA
关键词
Compliance; Implantable cardioverter-defibrillator; Older patients; Ventricular tachyarrhythmias; Wearable cardioverter-defibrillator; ACUTELY TERMINATING EPISODES; HIGH-RISK; VENTRICULAR-FIBRILLATION; ATRIAL-FIBRILLATION; CLINICAL-EFFICACY; DYSFUNCTION; INFARCTION; THERAPY; SHOCKS;
D O I
10.1016/j.hrthm.2018.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Use of the wearable cardioverter-defibrillator (WCD) in older patients has not been described previously. OBJECTIVE The purpose of this study was to assess WCD wear time, risk of arrhythmic events during WCD use, and implantable cardioverter-defibrillator (ICD) implantation rates after the end of WCD use in patients with age >= 65 years vs <65 years. METHODS We stratified 1732 patients with ischemic and nonischemic cardiomyopathy from the Prospective Registry of Patients Using the Wearable Defibrillator Registry into 2 subgroups by age: those with age >= 65 years and those with age <65 years. Wear time, arrhythmic events, and end-of-use decisions, specifically ICD implantation or improvement in ejection fraction, were evaluated for each age group. RESULTS There were 722 patients with age >= 65 years (41.7%) and 1010 patients with age <65 years (58.3%). Daily WCD wear time was longer in the older population (median 22.8 h/d (IQR 21.5 23.2) vs 22.3 h/d (IQR 19.5- 23.0); P <.001). Patients with age >= 65 years experienced higher event rates, per 100 patient-years, for any sustained ventricular tachycardia/ventricular fibrillation (31.95 vs 9.82; P =.027) and ventricular tachycardia/ventricular fibrillation treated with WCD shock (6.92 vs 2.37; P =.034), particularly with ischemic cardiomyopathy. Younger patients experienced a trend toward a higher event rate for atrial arrhythmias with nonischemic cardiomyopathy (150.07 vs 74.86; P =.055). At the end of WCD use, ICD implantation was more frequent in older patients (41.8% vs 36.5%; P =.034). CONCLUSION Older patients had good compliance with the WCD, presented with more frequent ventricular arrhythmias, and were more likely to receive an ICD at the end of WCD use. The WCD may play a role in risk stratification of the older population.
引用
收藏
页码:1379 / 1386
页数:8
相关论文
共 50 条
  • [31] The Wearable Cardioverter-Defibrillator (WCD) [Der tragbare Kardioverter-Defibrillator]
    Helms T.M.
    Müller A.
    Schwab J.O.
    Bänsch D.
    Karle C.
    Klingenheben T.
    Zugck C.
    Perings C.
    Herzschrittmachertherapie + Elektrophysiologie, 2015, 26 (2) : 129 - 133
  • [32] Ventricular tachycardia successfully treated with wearable cardioverter-defibrillator
    Grabowski, Marcin
    Gawalko, Monika
    Michalak, Marcin
    Cacko, Andrzej
    Opolski, Grzegorz
    KARDIOLOGIA POLSKA, 2017, 75 (12) : 1355 - 1355
  • [33] The wearable cardioverter-defibrillator: current technology and evolving indications
    Reek, Sven
    Burri, Haran
    Roberts, Paul R.
    Perings, Christian
    Epstein, Andrew E.
    Klein, Helmut U.
    EUROPACE, 2017, 19 (03): : 335 - 345
  • [34] Do we need the wearable cardioverter-defibrillator (WCD)?
    Klein, Helmut U.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 151 - 152
  • [35] Wearable cardioverter-defibrillator: friend or foe in suspected myocarditis?
    Blaschke, Florian
    Lacour, Philipp
    Dang, Phi Long
    Parwani, Abdul Shokor
    Hohendanner, Felix
    Walter, Thula
    Klingel, Karin
    Kuehl, Uwe
    Heinzel, Frank R.
    Sherif, Mohammad
    Boldt, Leif-Hendrik
    Pieske, Burkert
    Tschoepe, Carsten
    ESC HEART FAILURE, 2021, 8 (04): : 2591 - 2596
  • [36] Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator
    Goldenberg, Ido
    Erath, Julia W.
    Russo, Andrea M.
    Burch, Ashley E.
    Assmus, Birgit
    Bonderman, Diana
    McNitt, Scott
    Kutyifa, Valentina
    HEART RHYTHM, 2021, 18 (03) : 404 - 410
  • [37] Current status of wearable cardioverter-defibrillator use in Japan
    Tonegawa-Kuji, Reina
    Nishida, Taku
    Sumita, Yoko
    Miyamoto, Yoshihiro
    Kanaoka, Koshiro
    JOURNAL OF ARRHYTHMIA, 2024, 40 (04) : 998 - 1000
  • [38] The wearable cardioverter-defibrillator vest: Indications and ongoing questions
    Sandhu, Uday
    Rajyaguru, Chirag
    Cheung, Christopher C.
    Morin, Daniel P.
    Lee, Byron K.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2019, 62 (03) : 256 - 264
  • [39] An appropriate shock of the wearable cardioverter-defibrillator in an outpatient setting
    Kishihara, Jun
    Niwano, Shinichi
    Nakamura, Hironori
    Igarashi, Tazuru
    Ishizue, Naruya
    Fujiishi, Tamami
    Oikawa, Jun
    Murakami, Masami
    Fukaya, Hidehira
    Ako, Junya
    JOURNAL OF ARRHYTHMIA, 2016, 32 (01) : 67 - 69
  • [40] Wearable Cardioverter-Defibrillator after Myocardial Infarction REPLY
    Lee, Byron K.
    Pletcher, Mark J.
    Olgin, Jeffrey E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (06): : 600 - 601